FDA advisory panel recommends approval for Depo-Provera.
D000569:Americas; D001695:Biology; D001724:Birth Weight; D001835:Body Weight; D003257:Consumer Product Safety; D003267:Contraception; D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D019049:Developed Countries; D004194:Disease; D005193:Family Planning Services; D007230:Infant, Low Birth Weight; D007267:Injections; D007878:Legislation as Topic; D017258:Medroxyprogesterone Acetate; D009369:Neoplasms; D009656:North America; D010827:Physiology; D014481:United States
D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D017258:Medroxyprogesterone Acetate
Americas; Biology; Birth Weight; Body Weight; Cancer; Contraception; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--side effects; Contraceptive Methods; Depo-provera--side effects; Developed Countries; Diseases; Family Planning; Injectables; Legislation; Low Birth Weight; Medroxyprogesterone Acetate; Neoplasms; North America; Northern America; Physiology; Product Approval; United States